Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

NCT00431795 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

OTHER

Sponsor class

Stopped Due to poor accrual

Conditions

Breast Cancer

Interventions

DRUG: Pegylated liposomal doxorubicin (Caelyx)
DRUG: Epirubicin

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]